Explore the latest updates on managing plasma cell precursor conditions in this 20-minute medical lecture from Dana-Farber Cancer Institute, where Dr. Yuxin Liu discusses comprehensive strategies for handling smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS), along with current approaches to prevent disease progression. Gain insights into screening studies, management protocols, and emerging immune therapy treatments for these precursor conditions, drawing from the expertise of Dana-Farber's Center for Early Detection and Interception of Blood Cancers.
Management Updates for Smoldering Multiple Myeloma and MGUS - Prevention and Progression
Dana-Farber Cancer Institute via YouTube
Overview
Syllabus
Introduction
Screening Studies
Management
Immune Therapy
Taught by
Dana-Farber Cancer Institute
Related Courses
-
Early Detection and Prevention of Multiple Myeloma Progression
-
The PROMISE of Early Detection and Interception in Myeloma
-
Evaluating MGUS with Free Light Chain Assays in Clinical Practice
-
Continued Evolution of Therapy for Patients with Newly Diagnosed Multiple Myeloma
-
Future of Novel Next-Generation Therapy in the Management of Relapsed/Refractory Multiple Myeloma
-
Multiple Myeloma 101: Diagnosis, Prognosis, and Risk
